Bullish & Foolish
Full NRXP fundamentals All 466 on the Survival Watch

NRXPNRX Pharmaceuticals, Inc.

Is NRX Pharmaceuticals struggling financially?

Yes, by its own account. NRX Pharmaceuticals told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

0/100

Critical

Sector
Biotech/Pharma
Market cap
$154.1M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash and short-term investments

$26.7M

What NRX Pharmaceuticals told the SEC

…the impact of its continuing operations on the Company’s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared…

NRX Pharmaceuticals, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 103.4% share-count increase The company issued stock. Each share now owns 50.8% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt